Salicyladehyde

Salicyladehyde

SCHEMBL3379353

C1CN1.O=Cc1ccccc1O

nearest known ligand 0.78

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRIM24 O15164 1/20 0.78
TRIM33 Q9UPN9 1/20 0.78
ERN1 O75460 2/20 0.54
LMNA P02545 2/20 0.50
CDK4 P11802 1/20 0.50
CCND1 P24385 1/20 0.50
MEN1 O00255 1/20 0.50
THRB P10828 1/20 0.50
BLM P54132 1/20 0.50
KMT2A Q03164 1/20 0.50
TDP1 Q9NUW8 1/20 0.50
CA2 P00918 4/20 0.46
CA1 P00915 2/20 0.46
NFKB1 P19838 2/20 0.45
JUN P05412 1/20 0.45
NFE2L2 Q16236 1/20 0.45
CA4 P22748 1/20 0.44
NAT1 P18440 2/20 0.43
MAPT P10636 1/20 0.42
TRPA1 O75762 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Salicyladehyde SCHEMBL6694640 0.92 TRIM24 (0.67) TRIM24TRIM33ERN1LMNACDK4
Salicyladehyde SCHEMBL28887959 0.91 TRIM24 (0.95) TRIM24TRIM33ERN1LMNACDK4
Salicyladehyde SCHEMBL6917405 0.91 TRIM24 (0.95) TRIM24TRIM33ERN1LMNACDK4
Salicyladehyde SCHEMBL27901835 0.89 TRIM24 (0.62) TRIM24TRIM33ERN1LMNACDK4
Salicyladehyde SCHEMBL29386538 0.89
Salicyladehyde SCHEMBL15395 0.89
Salicyladehyde SCHEMBL901265 0.89 TRIM24 (1.00) TRIM24TRIM33ERN1LMNACDK4
Salicyladehyde SCHEMBL23389487 0.86 TRIM24 (0.95) TRIM24TRIM33ERN1LMNACDK4
Salicyladehyde SCHEMBL1176891 0.86 TRIM24 (0.95) TRIM24TRIM33ERN1LMNACDK4
Salicyladehyde SCHEMBL5842615 0.86 TRIM24 (0.95) TRIM24TRIM33ERN1LMNACDK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6392093-B1 USING OXIDATION CATALYST COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2002-05-21 US claimed
US-8268048-B2 Oxygen binding of nanoparticulate metal complexes UNIVERSITY OF KANSAS (US) 2012-09-18 US disclosed
US-20100089236-A1 Oxygen Binding of Nanoparticulate Metal Complexes NATIONAL SCIENCE FOUNDATION 2010-04-15 US disclosed
US-20070134338-A1 Methods for producing nanoparticulate metal complexes and altering nanoparticle morphology KANSAS UNIVERSITY OF, THE 2007-06-14 US disclosed
US-5250486-A Catalyst comprising a manganese compound, a chelate compound, a base and an unsaturated ketone or ether; controlled molecular weight; odorless; stabile thermal properties when blended with styrene resins GENERAL ELECTRIC COMPANY (US) 1993-10-05 US disclosed
EP-0491190-A2 Polyphenylene ether process and resin composition GENERAL ELECTRIC COMPANY (US) 1992-06-24 EP disclosed
US-5037943-A Oxidative coupling using alkaline catalysts system of manganese chelate and unsaturated or diketune or vinyl ether GENERAL ELECTRIC CO. (US) 1991-08-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070134338-A1 Methods for producing nanoparticulate metal complexes and altering nanoparticle morphology NCSTN, NCLN, NCDN TRIM24 3441/4885TRIM33 3361/4885ERN1 4400/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.